SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

June 27, 2012 12:27 ET

Implant Sciences Featured on Front Cover of Government Security News as Emerging Global Player in Explosive Trace Detection

GSN Is a Leading, Influential Publication Covering Homeland Security Issues

WILMINGTON, MA--(Marketwire - Jun 27, 2012) -  Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has been featured as the cover story in the June 2012 issue of Government Security News (GSN). With a circulation of over 45,000 subscribers comprised of leading government security officials, and a website with over 80,000 page views per month, GSN is considered the authoritative publication in the government security marketplace. The article can be viewed by clicking on the link:

The front cover article headlined, "U.S. Based Company Positioned to Become Global 'Player' in Explosives Trace Detection," details Implant Sciences' evolution into a homeland security focused business, led by a "roster of top-tier executives," bringing the Company's explosives trace detection (ETD) technology to what the company believes is a growing $1 billion industry. GSN describes Implant Sciences' management team and states in the article, "One security observer told GSN that he considers Implant Sciences to be one of the best managed small technology companies around."

The article cites government reports describing the change in security threats away from those that can be detected by x-ray equipment, such as guns and knives, to threats that are not detected by x-ray equipment, such as non-metallic explosives used in recent terrorist activities, including the underwear, shoe, and printer cartridge bombing attempts. Moreover, the article details how Implant Sciences' ETD devices offer a technology solution that can meet these changing threats. GSN also provides an overview of the importance of U.S. Transportation Security Administration's (TSA) approval for the Implant Sciences' products and how the Company's management team is focused on gaining such approvals.

GSN has also published several articles on Implant Sciences' recently announced key management appointments including top executives who have left its largest competitors in the ETD industry to join Implant Sciences.

To view the complete June 2012 issue of Government Security News visit:

About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 benchtop explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at

Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    Email Contact


    Investor Contact:
    Laurel Moody
    Email Contact